{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:30:15Z","timestamp":1773214215979,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"17","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["febs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The FEBS Journal"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>Coronavirus disease 2019 (COVID\u201019), the highly contagious illness caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS\u2010CoV\u20102), has spread across the globe, becoming one of the most challenging public health crisis of our times. SARS\u2010CoV\u20102 can cause severe disease associated with multiple organ damage. Cancer patients have a higher risk of SARS\u2010CoV\u20102 infection and death. While the virus uses angiotensin\u2010converting enzyme 2 (ACE2) as the primary entry receptor, the recent experimental and clinical findings suggest that some tumor markers, including CD147 (basigin), can provide an additional entry for SARS\u2010CoV\u20102 infection through binding to the viral spike (S) protein. In the absence of specific viral drugs, blocking of CD147 might be a way to prevent virus invasion. Identifying other target proteins is of high importance as targeting the alternative receptors for SARS\u2010CoV\u20102 might open up a promising avenue for the treatment of COVID\u201019 patients, including those who have cancer.<\/jats:p>","DOI":"10.1111\/febs.15499","type":"journal-article","created":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T19:25:50Z","timestamp":1596309950000},"page":"3677-3680","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Tumor markers as an entry for SARS\u2010CoV\u20102 infection?"],"prefix":"10.1111","volume":"287","author":[{"given":"Pu","family":"Xia","sequence":"first","affiliation":[{"name":"OncoRay \u2010 National Center for Radiation Research in Oncology Faculty of Medicine University Hospital Carl Gustav Carus Technische Universit\u00e4t Dresden Helmholtz\u2010Zentrum Dresden\u2010Rossendorf Dresden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3375-1500","authenticated-orcid":false,"given":"Anna","family":"Dubrovska","sequence":"additional","affiliation":[{"name":"OncoRay \u2010 National Center for Radiation Research in Oncology Faculty of Medicine University Hospital Carl Gustav Carus Technische Universit\u00e4t Dresden Helmholtz\u2010Zentrum Dresden\u2010Rossendorf Dresden Germany"},{"name":"Institute of Radiooncology \u2013 OncoRay Helmholtz\u2010Zentrum Dresden\u2010Rossendorf (HZDR) Dresden Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site Dresden Dresden Germany"},{"name":"German Cancer Research Center (DKFZ) Heidelberg Germany"},{"name":"National Center for Tumor Diseases (NCT) Partner Site Dresden Dresden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.11787"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17103452"},{"key":"e_1_2_8_4_1","first-page":"S1474\u20104422(20)3","article-title":"Neurological associations of COVID\u201019","author":"Ellul MA","year":"2020","journal-title":"Lancet Neurol"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30126-6"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.26218"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.17"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"e_1_2_8_10_1","unstructured":"Coronavirus disease (COVID\u20102019) situation reports The World Health Organization (WHO). Situation report \u2010 185."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/GO.20.00097"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14238"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102041"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0979-0"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104792"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30251-8"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2312-y"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.03.044"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01209-2"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050828"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14429"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11111803"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104759"},{"key":"e_1_2_8_25_1","article-title":"Meplazumab treats COVID\u201019 pneumonia: an open\u2010labelled, concurrent controlled add\u2010on clinical trial","author":"Bian H","year":"2020","journal-title":"medRxiv"},{"key":"e_1_2_8_26_1","article-title":"Association of COVID\u201019 disease severity with transmission routes and suggested changes to community guidelines","author":"Wu J","year":"2020","journal-title":"SSRN Electronic J"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2015.053"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btn334"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq311"}],"container-title":["The FEBS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ffebs.15499","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/febs.15499","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/febs.15499","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/febs.15499","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T21:33:36Z","timestamp":1693344816000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1111\/febs.15499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":28,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/febs.15499"],"URL":"https:\/\/doi.org\/10.1111\/febs.15499","archive":["Portico"],"relation":{},"ISSN":["1742-464X","1742-4658"],"issn-type":[{"value":"1742-464X","type":"print"},{"value":"1742-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]},"assertion":[{"value":"2020-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}